© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Ardelyx, Inc. (ARDX) stock declined over -2.91%, trading at $5.01 on NASDAQ, down from the previous close of $5.16. The stock opened at $5.20, fluctuating between $5.00 and $5.29 in the recent session.
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Employees | 267 |
Beta | 0.91 |
Sales or Revenue | $124.46M |
5Y Sales Change% | 11.237% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Ardelyx, Inc. (NASDAQ: ARDX) stock price is $5.01 in the last trading session. During the trading session, ARDX stock reached the peak price of $5.29 while $5.00 was the lowest point it dropped to. The percentage change in ARDX stock occurred in the recent session was -2.91% while the dollar amount for the price change in ARDX stock was -$0.15.
The NASDAQ listed ARDX is part of Biotechnology industry that operates in the broader Healthcare sector. Ardelyx, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dan Pavicich
Senior Director of Market Devel.
Ms. Susan Rodriguez
Chief Commercial Officer
Mr. Robert Felsch
Senior Vice President of Fin. & Chief Accounting Officer
Ms. Elizabeth A. Grammer
Chief Legal & Admin. Officer and Sec.
Ms. Kimia Keshtbod
Mang. of Corporation Communications & Investor Relations
Mr. Michael G. Raab
Pres, Chief Executive Officer & Director
Mr. Justin A. Renz CPA, M.S.T., MBA, MST
Chief Financial & Operations Officer and Treasurer
Dr. Laura A. Williams M.D., M.P.H.
Chief Medical Officer
Mr. David P. Rosenbaum
Chief Devel. Officer
Mr. Robert C. Blanks
Chief Regulatory Affairs & Quality Assurance Officer
Ms. Karen Harrigan
Senior Director Market Devel.
Ms. Charon Spencer Sr.
Chief HR Officer
Ms. Elizabeth A. Grammer Esq.
Chief Legal & Admin. Officer and Sec.
Ms. Caitlin Lowie
Vice President of Communications & IR
ARDX's closing price is 15.97% higher than its 52-week low of $4.32 where as its distance from 52-week high of $10.13 is -50.54%.
Number of ARDX employees currently stands at 267.
Official Website of ARDX is: https://www.ardelyx.com
ARDX could be contacted at phone 510 745 1700 and can also be accessed through its website. ARDX operates from 400 Fifth Avenue, Waltham, MA 02451, United States.
ARDX stock volume for the day was 5.75M shares. The average number of ARDX shares traded daily for last 3 months was 4.77M.
The market value of ARDX currently stands at $1.19B with its latest stock price at $5.01 and 236.85M of its shares outstanding.